Changes in Medical and Surgical Treatments of Glaucoma between 1997 and 2000 in France
Changes in Medical and Surgical Treatments of Glaucoma between 1997 and 2000 in France
复制标题
1997 年至 2000 年间法国青光眼内科和外科治疗的变化
DOI：
10.1177/112067210301304s06
复制
发表时间：
2003
影响因子：
1.7
通讯作者：
C. Le Pen
中科院分区：
文献类型：
--
作者：
C. Baudouin;J. Rouland;C. Le Pen
目的分析1997年至2000年法国青光眼治疗策略的量化变化。方法从法国诊断相关组织系统的国家数据库中提取外伤性小梁切除术和其他青光眼手术的数量，其中包括公立和私立医院的数据。平均住院时间和住院费用是根据法国卫生部发布的国家成本表估计的。每年使用拉坦前列素、布莫尼定或多唑胺+噻吗洛尔的固定组合治疗的患者数量是根据每种药物的限定日剂量从药品单位销售额中估计出来的。结果1997至2000年间，接受青光眼药物治疗的患者数量从每年41万人增加到73.4万人。这一增长与三种新的青光眼药物的引入有关：24.5万名患者接受了拉坦前列素(71.0%)、布莫尼定(28.8%)或多唑胺+噻吗洛尔的固定组合(0.2%)。在同一时期，接受医疗治疗的患者的手术率下降了47%，从5.9%下降到3.1%。青光眼干预措施的总数下降了4.6%(公立医院下降了12%，私立医院下降了0%)。这种相对的稳定性主要是由于从小梁切除术转向其他手术，主要是私人医院的新过滤程序。结论1997至2000年间，新的青光眼药物，主要是拉坦前列素和布莫尼定，改善了眼压控制和延迟手术，使接受青光眼相关治疗的患者的青光眼手术率降低了47%。
Purpose To analyze quantitative changes in glaucoma treatment strategies between 1997 and 2000 in France. Methods Numbers of ab externo trabeculectomies and other glaucoma surgeries were extracted from the national database of the French Diagnosis Related Group system, which includes data for both public and private hospitals. Mean lengths of stay and hospital costs were estimated using national cost scales published by the French Ministry of Health. Numbers of patients treated per year with latanoprost, brimonidine, or the fixed combination of dorzolamide + timolol were estimated from drug unit sales using defined daily doses for each drug. Results Between 1997 and 2000, the number of patients treated with a glaucoma drug increased from 410,000 to 734,000 patients per year. This increase was associated with the introduction of three new glaucoma drugs: 245,000 patients received latanoprost (71.0%), brimonidine (28.8%), or the fixed combination of dorzolamide + timolol (0.2%). During the same period, the surgery rate in patients receiving medical treatment declined by 47%, from 5.9% to 3.1%. The total number of glaucoma interventions declined by 4.6% (-12% in public hospitals and 0% in private hospitals). This relative stability resulted mostly from a shift from trabeculectomies to other procedures, mainly to new filtering procedures in private hospitals. Conclusions Between 1997 and 2000, new glaucoma drugs, primarily latanoprost and brimonidine, improved intraocular pressure control and delayed surgery, reducing the glaucoma procedure rate in patients receiving glaucoma-related medical treatment by 47%.